SOURCE Alere Inc.
Troubles at a plant acquired with St. Jude and continuing risks to closing the Alere deal linger over M&A spree.
Sales grew 29.7% in a year marked by acquisitions and new products, while comparable operations sales grew 3.2%.
Abbott will now pay a lower price to acquire Alere.
Abbott Laboratories appears poised to enjoy a fruitful year, though its litigation with former takeover target Alere could hold it back.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.